Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai’s Leqembi Now Approved in UAE
August 19, 2024
- Business Revamp “Just Getting Started”: Sumitomo Pharma CEO
August 19, 2024
- Tremfya Filed for Crohn’s Disease in Japan: J&J
August 13, 2024
- MSD Seeks Japan Nod for 21-Valent Pneumococcal Jab for Adults
August 13, 2024
- Opdivo-Yervoy Combo Filed for HCC in Japan
August 13, 2024
- Takeda Seeks CIDP Nod for Immunoglobulin Hyqvia in Japan
August 9, 2024
- Japan Patented Drug Market Breaks 7 Trillion Yen in FY2023: IQVIA
August 9, 2024
- Hizentra Now Available in Prefilled Syringe Form in Japan: CSL
August 9, 2024
- Nobelpharma to Launch Hypozincemia Drug Zintus on August 20
August 9, 2024
- Pfizer Earns Japan Nod for JN.1-Adapted COVID Vaccine
August 9, 2024
- Takeda’s Adzynma Approved in Europe, Launch Set for September
August 9, 2024
- Japan Ethical Drug Sales Down 5.5% in June: Crecon
August 9, 2024
- Daiichi, Merck Expand ADC Deal into Harpoon’s T-Cell Engager
August 8, 2024
- Chugai Gets Japan Rights to Roche’s Anti-TL1A IBD Drug
August 8, 2024
- Anapeine Restriction Forcing Sandoz to Curb Supply of More Local Anesthetics
August 7, 2024
- Sandoz to Discontinue Paxil AGs as Originator Pulls Out
August 7, 2024
- Kyorin, Jikei Startup Ink Option Deal for Respiratory Disease Treatment
August 7, 2024
- NCC Offshoot’s 1st CAR-T Therapy Set to Enter Clinic Next Year: CEO
August 7, 2024
- Santen Axes Diquas LX Outlook to Zero for Now as Supply Halt Continues
August 7, 2024
- Santen Snags Asian Rights to Cloudbreak’s Topical Pterygium Drug
August 7, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…